Harry Long is the inventor of Hedged Contango Capture and Hedged Convexity Capture and is the Managing Partner of ZOMMA, the world's most innovative strategy index creator.
Mr. Long is a globally recognized expert on the research and development of quantitative investment strategies. The ZOMMA IP portfolio of strategy indices is sought after by asset management firms, investment banks, hedge funds, principal trading organizations, index providers, ETP sponsors, and private equity firms to help them develop and deploy active manager-crushing quantitative investment strategies.
ZOMMA helps investors create long term value by replacing reckless emotional decision making with cutting-edge technology based upon objective evidence.
Mr. Long is a graduate of Rice University with a B.A. in Economics.
Note: Due to the sheer number of requests for bespoke quant strategies, research projects, and quant consulting services, we have instituted the following pricing for the non-exclusive licensing of our algorithms to institutions:
I. Exclusive commercial licenses for unique bespoke algorithms run six figures and up.
II. Non-exclusive AUM licensing fees for our strategy indices run 10 basis points and up for commercial licenses.
Please realize that we often get more than 3,000 e-mails per week. This means that we read everything that comes in, but we cannot respond to any email or message that does not include the sender's full name, phone number, request, and budget. Thank you for your understanding.
This Dubai-like pricing is necessary, because we can't freely give answers to tough problems which we have dedicated massive R&D capital to solving. World-class statistical talent is hugely expensive, valuable, and rare. Our clients recognize that outsourcing quant work to our firm and paying our fees represent a huge cost savings over hiring full time employees, and usually results in a far more profitable, turn-key solution.
PLEASE SEE WEBSITE FOR FULL DISCLAIMER: WWW.PUMPSTOPPER.COM
I produce high quality, original research free of charge for the public good. Please see the website for more information, and subscribe to The Pump Stopper email list to receive free, high quality research reports before the rest.
I am always committed to publishing the accurate truth. If you are involved with a company that has been mentioned in a report and find any factual errors, please submit a dispute to Seeking Alpha and it will be reviewed.
If you have any tips on companies misleading investors, please submit them on The Pump Stopper website. I always welcome collaboration and have absolute respect for your anonymity. There are multiple ways to submit documents anonymously, as outlined on the website, and I strongly recommend you send information this way.
And remember to always invest wisely.
I am the founder of Shaun Currie Research, an independent investment research firm that offers freelance, contract-based, and performance-based investment analysis and training for investment firms, newsletters, and blogs.
I have 10 years of investment experiences which include time spent at T Rowe Price (long only), Wells Capital Management (concentrated long only), and as the Director of Research at Manalapan Oracle Capital Management (long/short equity). I am currently completing my MBA at Northwestern University's Kellogg School of Management. I graduated with a BS in Business Administration from Villanova University.
Any content on this site is NOT investment, trading, legal, or tax advice, and none of the information available through this website is intended to provide tax, legal, investment or trading advice. Nothing provided through this content whether by the owner or posted by other writers constitutes a solicitation of the purchase or sale of securities/futures.
The content on this site is intended for informational purposes only, and should never be used as investment advice. Please do your own research before making any investment decisions.
We have investment positions in some of the securities we write about, and our positions are subject to change at any time. Nothing here is to be deemed a solicitation for investment nor investment advice. Please read our full legal disclaimer available on our blog. http://lazarusip.blogspot.com/
In addition to his ownership of the Dallas Mavericks basketball team, Cuban is an active investor in leading and cutting-edge technologies and continues to be a sought-after speaker.
Prior to his purchase of the Mavericks, Cuban co-founded Broadcast.com, the leading provider of multimedia and streaming on the Internet, in 1995, selling it to Yahoo! in July of 1999. Before Broadcast.com, Cuban co-founded MicroSolutions, a leading National Systems Integrator, in 1983, and later sold it to CompuServe.
Note: Mr. Cuban is not an active contributor to Seeking Alpha; rather, SA editors excerpt regularly from Mr. Cuban's public commentary.
If you choose to follow me please send me a message telling me which article got your attention
Love the trill of the hunt. Finding that little gem which is set to take off. I check daily and will trade partial position to accumulate shares for the longer haul.
I have been trading for a while, the first shares I ever bought were in the B.P. IPO. I have lived and worked all over the world in a number of capacities, including as a teacher and a Corporate Director. I now spend much of my time at Home with my four children ( hence my name), leading a much more settled life.
I believe that core growth and dividend returns are important, but a small manageable portion of your portfolio must always be invested in High risk High return scenarios. Don't bet more than you can afford and whenever possible play with the houses money. Start a position early. Start Small and accumulate.
I worked in New York's financial sector for almost exactly 20 years, mostly as a healthcare analyst (drugs, biotech, and medical devices), but also as an assistant research director, portfolio manager, and options strategist. My last formal job had me in charge of Value Line's premium priced "Select" and "Special Situation" products. The former highlights the company's top stock pick of each month and the latter introduces relatively small companies. I quit that job in June, 2009 for reasons that a dozen or so confidentiality agreements preclude my discussing. In September of that year, I launched 3DimensionalResearch.com (3DR), which allows me to continue doing what I was doing previously.
I am a strong believer in maximum transparency, in both personal and business relationships. So, in that vein:
A google search will show that my former employer sued 3DR and me in November, 2009 for copyright infringement, hot news misappropriations, and the proverbial kitchen sink. Although a search won't show this, unfortunately, I represented myself in a federal courtroom in December and, in accordance with the judge's instructions, the case was settled in a matter of minutes.
Additional Disclosure: 3DR has been a financial failure thus far, in terms of getting subscribers. I detest marketing and few people want to pay for information anymore, least of all from a no-name website. That said, the vast majority of my recommendations have done very well and my personal portfolio is doing extraordinarily well (65.5% in 2013) since I tend to follow most of my own recommendations, the "event driven special situations," in particular.
I am Semi-retired as a consultant (40+ years) in the fields of applied Pharmacology/Toxicology and Occupational Health & Safety, dealing with the role of drugs and chemicals in disease pathology and its treatment, complex exposure situations (use of medications, drugs of abuse & addiction and exposure to toxic workplace chemicals), toxicity and drug/chemical interactions and related management challenges.
I am now delving into the investment world for hobby and to increase retirement resources using my own capabilities and the many resources available. I am a novice investor and looking to learn at my pace and with assistance from others. I have strong scientific (pharmacology & health) and analytical training, experience and perspective. I have formal Risk Management training and experience and will use that to guide my investing decisions.
From an investment perspective, I am looking for a combination of stable and proven income generating companies, balanced with managed risk associated with biotechnology equities with large upside potential, ones leading the charge into research and development of ground breaking biological solutions to society' needs. I plan to focus on the biotechnology sector as that is where my strength lies. I look forward to learning from the SA contributors and where appropriate making a contribution with my perspective and views.
I am a psychologist at the University of Massachusetts/Amherst. I am on our campus’s Institutional Review Board, which must conclude that proposed studies involving human subjects are conducted ethically and are designed well enough so that any risks involved are justified by the likely benefits obtained.
I teach about analytical reasoning, leadership skills, reconciling apparently incompatible positions, designing, implementing, and evaluating policies, and how to critically evaluate competing health claims based on the samples studied and methods of data collection and analysis used.
Most of my investments involve owning medical industry stocks.
Lares Capital, a long/short fund that specializes in small caps, option strategies, and low-liquidity equities. The fund invests in both domestic and foreign securities.
You can contact us at email@example.com.
Suhail Capital Management is a Cayman Domiciled Private Investment Firm. We focus on event driven long/short opportunities in what we believe to be seriously mispriced global listed securities.
I am an engineer by training who now invests full-time, having built up a reasonable enough nest egg through saving and investing via fundamental analysis rooted in a determination of intrinsic value. I have done well in the market throughout my investing career by running 60%-100% net exposure and 120%-160% net exposure. I view shorting as a wise hedging strategy against my long market exposure, but I have managed to make money on the short side over the years.
Jeffrey Dow Jones is the managing editor for Alpine Advisor. He has previously worked for PaineWebber/UBS and Ford Motor Credit Company, and he spent the last decade co-managing a group of hedge funds. He holds a degree in Business Economics with a specialization in Computer Programming from The University of California - Los Angeles.
He publishes a free weekly newsletter at AlpineAdvisor.info.
I'm an independent equity researcher, writer and investor based in Amsterdam. My primary focus is on the micro-cap segment of the market. I also work for pension funds as a member of the Board and Investment Committee. Lastly, I enjoy soccer, sports in general and brewing the best coffee one can make at home.
We are a research group that consults hedge fund and high-net worth clients. We specialized in identifying special opportunities from both the long and short side. The writer for 3D Analytics has professional traded for hedge funds for 10+ years and specializes in 1) finding hidden, unrecognized value, 2) shorting overvalued stocks, and 3) arbitrage situations. The articles are written solely by him, but has a group that assist him in finding opportunities, basic research, and editing.
I hold MSc. in Electrical Engineering, speak four languages (English, French, Greek, German) and have lived in the U.S. for many years. I am also a freelance writer with one of the highest Followers per Article (F/A) rates in Seeking Alpha. My F/A rate in Seeking Alpha is above 30.
After creating "Nathan's Bulletin" (a subscription-based investment guide for investors who can't afford a financial advisor), I launched a subscription-based Premium Service in Seeking Alpha entitled "A Fundamental Investor's Stock Club" which includes an unparalleled, actively-managed and high-return Portfolio of unknown and/or underfollowed stocks. Regularly updated and detailed lists in my Premium Posts PROVE these high returns. For reference, when I was managing money in the early 2000s, the annual ROI of my Portfolio consistently exceeded 50%. My Premium Research is based on a comprehensive review of company-specific factors, macro conditions, competitors and the industry trends.
When it comes now to my publicly-available picks and my free Seeking Alpha articles, I have a success rate of over 80%, an average return per recommendation of over 30% and a 5-star rating according to TipRanks.com, which is the highest category quality ranking used to evaluate financial experts. TipRanks.com is a comprehensive investing tool that allows private investors and day traders to see the measured performance of anyone who publicly provides financial advice. TipRanks.com collects data, evaluates and ranks 5,000 financial bloggers and 9,000 financial experts.
After almost 30 years of investing experience in the international markets (U.S., Canada, Australia, Europe), I have formulated a deep understanding of valuation analysis and my investment philosophy is firmly grounded in Ben Graham-style value-oriented opportunities that often have an assymetric risk/reward profile. On that front, I have created a unique proprietary database with thousands of publicly-traded companies per sector, which helps me spot the bargains and the bubbles before many investors find them.
The Fraud Research Institute ("FRI") specializing in the research and discovery of financial scandals and corporate malpractice in the United States with an emphasis on the small cap markets.
Our business model is to publish the highest quality and most compelling professional research reports that highlight all material information necessary for short-biased traders to identify superior risk-to-reward trade ideas that are primarily a result of market inefficiencies created by the artificial demand from stock promotion (pump & dump) campaigns.
We identify Wall Street's biggest frauds and profit from them.
A biopharma portfolio manager as well as a sell-side biotechnology analyst for the past 20 years. In 2005, formed the Lyons Share Group, providing independent biopharma research and consulting services to institutional portfolio managers with regard to investments in the sector that fit the market capitalzation and investment styles. MBA from the Fuqua School of Business, Duke University and a Chartered Financial Analyst.
I run long-only family office assets with a focus on small-cap deep-value securities. In many cases value is hidden below the surface of simple financial metrics and screenable criteria. I'll publish notes on Seeking Alpha when I have something insightful to share that is not getting proper treatment from mainstream research channels. Please note, I'm very busy trying to relax. Writing articles and responding to emails is an after-hours activity. What I lack in publishing regularity, I hope to offset through quality of dialogue. I have met some ridiculously talented and brilliant analysts through Seeking Alpha. This is my true (selfish) motive for re-engaging in such a public forum.
CFA, Alternative investment professional, equity bias but cap structure agnostic. I spent a year on the PHLX options exchange, and worked as an integral member of the investment committee of a medium sized L/S hedge fund in NY, as well as their head-trader, for 6 years.
My personal bias is towards special situations, and smaller cap names, . I use a value-investing orientation, though I try to marry actual catalysts and a top-down understanding to any thesis I present.
Daniel B. Ravicher is a registered patent attorney who frequently consults with investment banks, hedge funds, and individual investors on legal issues that may materially affect the value of publicly traded companies. In addition to private consulting, Mr. Ravicher also regularly publishes articles covering such issues. He is not an investment adviser and the opinions expressed are not legal, financial or any other kind of advice.
In his legal practice, Mr. Ravicher provides transaction and litigation legal services to clients with respect to a wide range of technologies, including pharmaceuticals, biotechnology, software, the Internet, mobile devices, mechanical devices, consumer products and business methods. He represented the successful plaintiffs in the Supreme Court case invalidating patents on human genes and has twice testified before Congress on the topic of patent reform. Repeatedly named one of 'The 50 Most Influential People in IP' by Managing Intellectual Property and named Appellate Lawyer of the Week by the National Law Journal, Mr. Ravicher has appeared as a guest on national television, been quoted in articles by the Wall Street Journal, Bloomberg, the New York Times, the Financial Times and other publications, and spoken at dozens of national and international conferences on issues relating to patent and technology law.
Mr. Ravicher received his law degree from the University of Virginia School of Law, where he was the Franklin O'Blechman Scholar of his class, a Mortimer Caplin Public Service Award recipient and an Editor of the Virginia Journal of Law and Technology, and his bachelors degree in materials science magna cum laude with University Honors from the University of South Florida. He is admitted to the United States Supreme Court, the Courts of Appeals for the Federal, 2nd and 11th Circuits, the District Courts for the Southern and Eastern Districts of New York and the Southern and Middle Districts of Florida, the States of New York and Florida, and the United States Patent and Trademark Office.
Tom Shaughnessy is owner of SecretCaps.com, an independent investor and analyst. He has been investing in the stock market since the age of twelve. His style is comprehensive and includes multi-layered research on a concentrated set of stocks. Tom enjoys constructive dialogue regarding various investment ideas and theories.
Tom enjoys intensive research on prospective investments. This includes valuation estimates and modeling, CEO and management interviews, product and expansion overviews, future prospects, financial analysis and the current state of affairs at the company. Moreover, Tom's articles have a focus on micro-cap companies whose potential have flown under the radar.
In his leisure time Tom enjoys playing racquetball on a competitive level.
Markman Advisors specializes in the strategic analysis of investment opportunities presented by intellectual property—and in particular, patent—litigation activities. We are all USPTO-registered patent attorneys with decades of combined experience in patent litigation, licensing and procurement. After many years practicing at some of the world’s largest and well-known law firms, we established and now run a premier intellectual-property boutique law firm, where we continue to practice patent litigation.
We have litigated numerous high-stakes patent cases in federal district courts throughout the country, as well as at the appellate level before the Federal Circuit. We are also experienced in USPTO proceedings, and have advised clients across a wide swath of technical areas with respect to patent-related matters.
Our base of former and current legal clients is diverse, from technology start-ups to some of the world’s largest and most well-known corporations. Collectively, we have led those clients through numerous Markman hearings, summary judgment motions, trials and appeals – on both the offensive and defensive sides of a case.
Our patent litigation experience, coupled with our knowledge of the market for "patent play" stocks, is the alpha we bring to each patent litigation-driven investment opportunity.